GlassScriptPhysician profile
Ruchir Agrawal
NPI 1831285618
$2,710.93
in general payments reported to CMS, 2019-2025
20 companies · $775 in 2025
The $775 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.93 · 2020: $92.67 · 2021: $118 · 2022: $286 · 2023: $758 · 2024: $617 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,034 · Education: $97.39 · Consulting Fee: $18.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,033.83 |
| Education | $97.39 |
| Consulting Fee | $18.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $443.64 | 2021-2025 | Dupixent |
| Genzyme Corporation | $394.72 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $248.53 | 2020-2025 | Cuvitru, Takhzyro |
| Biocryst US Sales Co., LLC | $226.25 | 2023-2025 | Orladeyo |
| Astrazeneca Pharmaceuticals LP | $221.20 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Novartis Pharmaceuticals Corporation | $207.07 | 2019-2025 | |
| Glaxosmithkline, LLC. | $189.42 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Grifols USA, LLC | $150.95 | 2023-2025 | Xembify |
| Kaleo, INC. | $136.36 | 2019-2023 | Auvi-Q |
| Abbvie INC. | $120.78 | 2023-2024 | Rinvoq |
| Pharming Healthcare, INC. | $82.22 | 2022-2025 | Ruconest |
| Csl Behring | $55.23 | 2021-2024 | Haegarda |
| Phadia US INC. | $52.98 | 2021-2023 | Immunocap |
| Leo Pharma INC. | $51.63 | 2023-2024 | Adbry |
| Optinose US, INC. | $27.69 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $25.31 | 2022 | |
| Dermavant Sciences, INC. | $24.07 | 2024 | Vtama |
| Aimmune Therapeutics, INC. | $22.84 | 2022 | |
| Adma Biomanufacturing LLC | $18.04 | 2023 | |
| Pfizer INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruchir Agrawal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.